We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Binge Eating in Obese Patients in Primary Care

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00537810
First Posted: October 1, 2007
Last Update Posted: December 12, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Carlos Grilo, Yale University
  Purpose
This study will test the effectiveness of two empirically-supported but distinct treatments for recurrent binge eating in obese patients: 1) Cognitive Behavior Therapy, using a pure self-help approach and 2) sibutramine, an anti-obesity medication also found to have efficacy for binge eating. Self-help Cognitive Behavior Therapy and sibutramine will be administered alone and in combination in a primary care setting.

Condition Intervention Phase
Obesity Binge Eating Drug: Sibutramine Drug: Placebo Behavioral: Self-help CBT + Sibutramine Behavioral: Self-help CBT + Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment of Binge Eating in Obese Patients in Primary Care

Further study details as provided by Carlos Grilo, Yale University:

Primary Outcome Measures:
  • Binge Eating (Remission) [ Time Frame: 4 months treatment; 6 and 12 month follow up post treatment ]
    Remission from binge eating (zero binge episodes during previous 28 days)

  • BMI [ Time Frame: 4 months treatment ]

Enrollment: 104
Study Start Date: September 2007
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sibutramine
Sibutramine 15 mg daily
Drug: Sibutramine
15 mg daily
Other Name: Meridia
Placebo Comparator: Placebo
Placebo Daily
Drug: Placebo
Daily
Experimental: Placebo/CBTsh
Placebo and Self-help CBT Placebo daily, Cognitive behavioral self-help manual for binge eating
Behavioral: Self-help CBT + Sibutramine
Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
Experimental: Sibutramine/CBTsh
Sibutramine and Self-help CBT 15 mg daily Cognitive behavioral treatment manual for binge eating
Behavioral: Self-help CBT + Placebo
Cognitive behavioral treatment manual for binge eating Placebo daily

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Obese (BMI >= 30)

Exclusion Criteria:

  • Medication regimen that represents medical contraindication to sibutramine
  • Serious unstable or uncontrolled medical conditions that represent contraindication to sibutramine
  • Pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00537810


Locations
United States, Connecticut
Yale Internal Medicine Associates (YIMA)
New Haven, Connecticut, United States, 06510
Yale-New Haven Hospital (YNHH) Primary Care Center (PCC)
New Haven, Connecticut, United States, 06510
Yale Psychiatric Research at Congress Place
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Principal Investigator: Carlos M. Grilo, PhD Yale University
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Carlos Grilo, Professor of Psychiatry, Yale University
ClinicalTrials.gov Identifier: NCT00537810     History of Changes
Other Study ID Numbers: 0501027352
R01DK073542-01A1 ( U.S. NIH Grant/Contract )
First Submitted: September 27, 2007
First Posted: October 1, 2007
Results First Submitted: June 19, 2014
Results First Posted: December 12, 2014
Last Update Posted: December 12, 2014
Last Verified: December 2014

Keywords provided by Carlos Grilo, Yale University:
Obesity
Binge eating
Sibutramine
Self-help
Primary care

Additional relevant MeSH terms:
Binge-Eating Disorder
Bulimia
Feeding and Eating Disorders
Mental Disorders
Hyperphagia
Signs and Symptoms, Digestive
Signs and Symptoms
Sibutramine
Antidepressive Agents
Psychotropic Drugs
Appetite Depressants
Anti-Obesity Agents